Includes Extensive Data Showing that CM-101, Chemomab s CCL24-Neutralizing Antibody, Interrupts the Fibro-Inflammatory Processes that Lead to PSC
TEL AVIV, Israel, June 28, 2023 /PRNewswire/ Chemomab Therapeutics Ltd. (Nasdaq: CMMB), .
Share this article
Share this article
TEL AVIV, Israel, Feb. 2, 2021 /PRNewswire/ Chemomab Ltd., a clinical-stage biotech company focusing on discovery and development of innovative therapeutics for fibrosis-related diseases, today announces enrollment of the first patient in a phase IIa clinical trial of CM-101 for the treatment of patients with primary sclerosing cholangitis (PSC).
The SPRING phase IIa study is a multicenter, double-blind, placebo-controlled study designed to evaluate the safety and efficacy profile of CM-101 in adult subjects with PSC over 15 weeks of treatment. The study is being conducted at multiple leading sites in the United Kingdom and Israel, and will enroll up to 45 patients randomized in a 2:1 ratio between CM-101 and placebo.